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This	 article	 reviews	 recent	 developments	 in	 research	 and	 patient	 care	 and	 future	
trends	in	the	discipline.	The	section	on	basic	mechanisms	of	allergic	diseases	sum‐
marizes	the	current	status	and	defines	research	needs	in	structural	biology,	type	2	
inflammation,	 immune	 tolerance,	 neuroimmune	 mechanisms,	 role	 of	 the	 microbi‐
ome	and	diet,	environmental	factors,	and	respiratory	viral	infections.	In	the	section	
on	diagnostic	challenges,	clinical	 trials,	precision	medicine	and	 immune	monitoring	











novel	 treatment	modalities	 of	 allergic	 diseases	 and	 immunological	
disorders.	It	is	generally	expected	that	drug	development	in	the	next	
decades	will	 show	a	 significant	 shift	 from	chemicals	 to	biologicals.	
After	more	 than	20	 years	without	 any	 breakthrough	drug	 becom‐
ing	available	for	patients,	several	disciplines	including	allergology	are	
now	experiencing	extraordinary	 times	with	 the	 recent	 licensing	of	
several	major	biological	drugs	and	novel	allergen‐specific	 immuno‐





and	 endotyping	 of	 diseases	 for	 customized	 patient	 care,	 which	 is	
termed	 stratified	 medicine,	 precision	 medicine,	 or	 personalized	

















2  | BA SIC MECHANISMS OF ALLERGIC 
DISE A SES—KE Y QUESTIONS
2.1 | Structural and functional biology of allergens—
where are we at?
Cloning	of	allergen	cDNAs	and	sequencing	of	purified	natural	aller‐
gens	have	so	far	yielded	919	officially	accepted	allergenic	proteins	
listed	 in	 the	 database	 of	 the	 WHO/IUIS	 Allergen	 Nomenclature	
Sub‐Committee	 (http://www.aller	gen.org/;	 accessed	 11/2018).	








molecules,	 and	 novel	 therapeutic	 concepts	 in	 allergen‐specific	 immunotherapy	 for	
airway	disease.	Unknowns	and	future	research	needs	are	discussed	at	the	end	of	each	
subsection.
K E Y W O R D S
allergy,	exposome,	microbiome,	neuroimmune,	respiratory	viral	infections
How to expand the understanding of allergens and 
allergic sensitization?










•	 Perform	 studies	 on	 signal	 transduction	 initiated	 by	 al‐
lergens	in	innate	immune	cells
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cross‐reactivities	 between	 related	 allergens,20	 or	 the	design	of	 al‐
lergens	with	 altered	 IgE	 epitopes	 as	 vaccine	 candidates	 for	AIT.21 
The	 location	of	 IgE‐binding	 epitopes	 can	be	determined	based	on	







families	 (http://www.medun	iwien.ac.at/allfa	m/).	 This	 insight	 has	
now	become	mainstream	knowledge	and	indicates	that	the	biologi‐
cal	functions	of	allergens	might	be	linked	to	their	allergenicity.26
Various	 explanations	 for	 the	 existence	 of	 the	 allergic	 immune	
response	have	been	brought	 forward	 including	the	toxin	hypothe‐
sis,27,28	the	danger	theory,29	and	the	allergic	host	defense	model.30 
Unequivocally,	 these	 authors27‐30	 argue	 that	 it	 is	 a	 common	 mis‐
conception	to	regard	allergens	as	generally	harmless	environmental	
substances.	 Allergens	 interact	 with	 innate	 immune	 receptors	 (eg,	
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2.2 | Mechanisms of type 2 inflammation and 
immune tolerance to allergens




ceptors.	Generally,	 it	 is	considered	that	a	type	2	 immune	response	
is	 the	 main	 player	 in	 the	 pathogenesis	 of	 eosinophilic	 asthma,	 al‐
lergic	 rhinitis,	 chronic	 rhinosinusitis	with	nasal	 polyps,	 eosinophilic	
esophagitis,	 and	 extrinsic	 atopic	 dermatitis.40	 The	 type	 2	 immune	






and	 IL‐25,	 IL‐33,	 and	 TSLP	 from	 tissue	 cells,	 particularly	 epithelial	
cells.43,44	 (Figure	 1)	 GATA3	 is	 the	 key	 transcription	 factor	 for	 the	














endotype	 such	 as	 the	 IL‐5‐high,	 IL‐13‐high,	 or	 IgE‐high	 endotype,	
and	 their	 dominance	 differs	 between	 allergic	 diseases	 (Figure	 1).	
Omalizumab	 targeting	 IgE,	mepolizumab,	 reslizumab	 targeting	 IL‐5,	
benralizumab	 targeting	 the	 IL‐5	 receptor,	 and	 dupilumab	 targeting	
the	IL‐4	and	IL‐13	common	receptor	alpha	chain	are	some	of	the	bio‐
logicals	currently	available	to	control	type	2	inflammation.
2.2.2 | T‐regulatory and B‐regulatory cells
Immune	regulation	is	an	important	function	of	the	immune	system	


















•	 Mechanisms	 of	 viral	 infections	 in	 exacerbation	 of	 type	 2	
diseases
•	 Local	 immune	 deficiency	 caused	 by	 a	 type	 2	 immune	
response
•	 Effect	of	type	2	immune	responses	to	chronicity




chronicity	 of	 complex	 type	 2	 immune	 response–related	
diseases





•	 Disease‐modifying	 effect	 of	 different	 type	 2	 immune	 re‐
sponse‐targeting	treatments
•	 Combination	treatments	with	allergen	immunotherapy










•	 Relationship	 of	 resident	 tissue	 cells	 and	 their	 interaction	



















2.3 | Neuroimmune mechanisms in allergic 
inflammation
It	is	becoming	increasingly	clear	that	immune	cells	do	not	act	alone	
and	 that	 cross	 talk	 and	 reciprocal	 regulation	 between	 neural	 and	
immune	 systems	 are	 essential	 in	 the	 pathophysiology	 of	 allergic	
diseases	including	allergic	asthma,	atopic	dermatitis,	and	food	aller‐
gies.55,56	 Immune	and	neuronal	 cell	 types	are	 found	 in	 large	num‐
bers	at	 skin	and	mucosal	barrier	 surfaces	and	are	 in	close	contact	
with	 each	 other	 forming	 a	 neuronal‐immune	 cell	 network.57‐60 
Both	immune	and	neural	cells	detect	and	respond	to	environmental	
threats	and	harmful	stimuli	including	allergens.	Innate	and	adaptive	
immune	 responses	 mediate	 proinflammatory	 responses	 by	 secre‐
tion	of	cytokines	(eg,	IL‐4,	IL‐5,	IL‐9.	IL‐13,	IL‐25,	IL‐31,	IL‐33,	TSLP),	
chemokines	 (eg,	 histamine),	 and	 other	 lipid	 mediators	 (eg,	 leukot‐
rienes)	 on	 encountering	 allergens.	Within	 these	 cytokines,	 a	 bio‐
logical	targeting	IL‐31	was	shown	to	treat	itch	in	atopic	dermatitis.	
In	 addition	 to	mediating	 allergic	 responses	 via	 immune	 responses,	
these	proinflammatory	mediators	also	directly	activate	sensory	neu‐




neuromedin	U	 (NMU),	 calcitonin	 gene–related	 peptide,	 vasoactive	
intestinal	peptide,	acetylcholine,	and	norepinephrine	that	signal	im‐
mune	cells.55	 In	 the	airways,	 calcitonin	gene–related	peptide	 is	 re‐
leased	by	sensory	nerves,	which	has	been	shown	to	inhibit	dendritic	
cell	maturation	and	allergen‐specific	T‐cell	 responses.61	 In	 the	gut,	
ILC2	cells	were	shown	to	express	Nmur1,	a	receptor	for	the	neuro‐
peptide	NMU.	ILC2s	live	in	close	proximity	to	NMU‐producing	nerve	




Future prospects for research on neuroimmune regu-
lation of allergic diseases
•	 The	 mechanisms	 underlying	 allergen‐induced	 release	 of	
proinflammatory	mediators	and	neural	activation	(reflexes)





•	 Development	 of	 pharmacological	 compounds	 targeting	








asthma,	 norepinephrine	was	 found	 to	 stimulate	 IgE	 production	on	
binding	β2‐adrenergic	receptors	and	activating	B	cells.63,64	A	positive	








lifestyle	 changes	 and	 indoor	 and	 outdoor	 environmental	 pollut‐
ants67‐69	are	suspected	to	keep	our	immune	system	in	a	constant	
state	 of	 low‐grade	 inflammation.	 Apart	 from	 direct	 effects	 of	
outdoor	pollutants	on	humans,	pollen‐producing	plants	are	them‐




factors	 induce	 epigenetic	 changes	which	 are	 associated	with	 al‐
lergic	diseases	(summarized	in	Ref.72).
The	exposome	includes	the	entire	environmental	exposures	that	
a	 person	 experiences,	 from	 conception	 throughout	 the	 whole	 life	
(Figure	2).73	A	 clear	missing	 knowledge	 is	 the	 lack	of	 thorough	ep‐
idemiological	 studies	 encompassing	 a	 holistic	 approach	with	 expo‐
some	and	reactome	(response	patterns)	over	a	life	span.	This	wide	gap	













































foods	provide	 the	 fuel	 for	microbial	metabolic	activities.81	For	ex‐







Despite	 increasing	 awareness	 of	 the	 importance	 of	 microbi‐
ome‐diet	interactions	in	health	and	disease,	the	molecular	basis	for	
these	multidirectional	functional	interactions	is	only	beginning	to	be	
Hot spots in environmental health research
•	 Moving	 from	 associations	 to	 causalities	 and	 molecular	
mechanisms




•	 Development	 of	 devices	 for	 personal	 monitoring	 of	 real‐




•	 Define	personal	 thresholds	 for	environmental	 triggers	 for	
allergic	symptoms





2.6 | Respiratory viral infections and allergy
Respiratory	viruses	are	the	most	common	causes	of	respiratory	dis‐
eases,	which	can	be	linked	with	the	potentiation	of	acute	and	chronic	
respiratory	 mucosal	 inflammation.	 This	 usually	 occurs	 through	










of	 initial	 host	 responses	against	 viral	 infection.	 Such	nasal	 epithe‐




self‐limiting,	 could	 trigger	 chronic	 type	 2	 inflammatory	 responses	
via	excessive	release	of	chemokines	and	cytokines	into	the	airways.	




cant	 increase	 in	 interferons	 (IFN‐α,	 IFN‐γ,	 IL‐29),	 proinflammatory	








3  | DIAGNOSTIC CHALLENGES AND 
REGUL ATORY CONSIDER ATIONS
3.1 | Clinical trials for the treatment of allergic 
diseases
In	 2008,	 the	 Committee	 for	 Medicinal	 Products	 for	 Human	 Use	
(CMPH)	of	the	European	Medicine	Agency	(EMA)	has	implemented	
the	“Guideline	on	the	Clinical	Development	of	Products	for	Specific	
Immunotherapy	 for	 the	 Treatment	 of	 Allergic	 Diseases	 (CHMP/
EWP/18504/2006)”	 (Available	 from:	 http://www.ema.europa.eu/
docs/en_GB/docum	ent_libra	ry/Scien	tific_guide	line/2009/09/
WC500	003605.pdf	 and	 ref.103)	 and	 by	 this	 has	 set	 methodologi‐
cal	 standards	 for	 clinical	 trial	 designs	 for	AIT	 regarding	phase	 I‐III	










cal	principles	 in	 the	design	of	 these	 trials	would	be	preferable	 for	
all	 parties	 involved.107	 Hence,	 the	 Immunotherapy	 Interest	 Group	
(IT‐IG)	of	the	European	Academy	of	Allergy	and	Clinical	Immunology	
(EAACI)	has	elaborated	different	 task‐force	projects	 regarding	 im‐



















Unknowns and future prospects for research in viral 










•	 Novel	 anti‐viral	 treatments	 based	 on	 newly	 identified	
mechanisms










only	be	achieved	by	 international	 collaboration	of	 clinical	 experts,	
methodologists,	and	regulatory	authorities.109,110










Examples of unknowns and future prospects for har-
monization of AIT trial design and interpretation of 
trial results (modified to references107,109,110)
•	 Evaluation	and	validation	of	possible	biomarkers	of	predic‐
tive	value	for	efficacy15
•	 Further	 validation	of	 clinical	meaningful	 primary	 and	 sec‐
ondary	endpoints108
•	 Clinically	 justified	definitions	of	 relevant	 treatment	effect	
sizes






ness,	 disease‐modifying	 properties,	 and	 the	 duration	 of	
both	in	asthmatic	patients






metabolomics,	 proteomics,	 epigenomics,	 transcriptomics,	 lipidom‐
ics,	and	microbiomics	to	generate	vast	global	datasets,	and	advanced	
bioinformatics	 to	 interrogate	and	 interpret	 the	datasets	using	ma‐
chine	 learning	and	artificial	 intelligence	 (Figure	4).113	Such	analysis	
of	population‐based	datasets	can	reveal	novel	insights	to	underpin	
therapeutic	 selection	 from	 an	 expanded	 range	 of	 precise	 biologi‐
cals.114	Examples	are	emerging	from	patients	with	inborn	errors	of	
immunity	 (IEI)	 in	whom	the	genetically	defined	defect	can	be	spe‐




Technological	 advances	 in	 immune	 monitoring	 capability	 are	
augmented	by	highly	standardized	or	chimeric	recombinant	allergens	
and	peptides	(B‐	and	T‐cell	epitope‐based).	Exponential	advances	in	
microarrays,	 time‐of‐flight	 mass	 cytometry	 (CyTOF),	 basophil	 ac‐
tivation	 tests,	 next‐generation	gene	 sequencing,	 and	RNA‐seq	are	
generating	huge	enabling	datasets.15,115,116,119‐123	The	risk	that	small	




immunoprofiling	 of	 relevant	 cell	 subsets	 in	 individuals	 before	 and	
during	AIT.	Better	dissection	of	mechanisms	underlying	allergic	dis‐
eases	informs	better	tailoring	of	therapies.115,116,119‐122,124,125
3.3 | Allergic rhinitis and nonallergic rhinitis
Chronic	 rhinitis	 (CR)	 is	 one	 of	 the	most	 common	 diseases	 glob‐
ally,	with	a	considerable	financial	burden.126,127	At	present,	CR	is	







•	 Minimization	 of	 adverse	 side	 effects	 (especially	 anaphy‐



















































3.4 | New approaches to the diagnosis and 
treatment of drug hypersensitivity reactions
Drug	 hypersensitivity	 reactions	 (DHRs)	 are	 defined	 as	 adverse	
effects	 of	 pharmaceutical	 formulations	 that	 clinically	 resemble	
allergy.	Drug	 allergies	 are	 defined	 as	DHRs	 for	which	 a	 definite	




are	 essential	 for	 treatment	 of	 common	diseases.138,139	Based	on	







between	 immediate	 and	 nonimmediate	DHRs.13,136,141	 These	 data	




















cost‐effective	 technique	 that	 activates	 inhibitory	mechanisms	 and	
permits	 patients	 to	 receive	 the	 first‐choice	 medications	 to	 which	
they	are	allergic.149,150











•	 The	mechanism	of	 inhibition	 in	 rapid	drug	desensitization	
procedure
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4  | UNMET NEEDS AND FUTURE 
RESE ARCH ARE A S IN TRE ATMENT OF 
ALLERGIC DISE A SES
4.1 | How to treat food allergy in the future: new 
developments and concepts
We	 are	 observing	 a	 pandemic	 increase	 in	 food	 allergy	 and	 ap‐
proaching	an	era	of	efficient	treatments.	In	peanut	allergy	oral	im‐
munotherapy	(OIT),	phase	III	studies	on	AR101152	in	peanut	allergic	





sitization;	however,	 all	 current	 applications	are	 linked	 to	an	avoid‐













and	 time	 of	 treatment,	 and	 the	 existence	 of	 only	 few,	 suboptimal	
biomarkers	 that	 predict	 treatment	 response	 and	 how	 to	 perform	
multifood	 OIT.13,157,158	 These	 limitations	 are	 addressed	 in	 numer‐
ous	 treatment	 approaches:	 (a)	 peptide	 immunotherapy	 targeting	
the	T‐cell	 compartment	 and	 lacking	 IgE	 cross‐linking159‐161;	 (b)	 hy‐
poallergenic	variants	of	allergens	or	extracts	by	chemical	or	thermal	
modification162,163	 or	 mutations	 which	 combine	 reduced	 desensi‐





Recent	methodological	 developments	on	 cloning	 and	 antibody	
generation	 from	 single‐cell	 sorting	 of	 allergen‐specific	 B	 cells	will	
allow	 novel	 insights	 on	 the	 nature	 of	 peanut‐specific	 B‐cell	 re‐
sponses	and	may	give	rise	to	novel	high‐affinity	blocking	antibody	
treatments.173






III	 trials	demonstrated	efficacy	by	blocking	 the	 IL‐4/IL‐13	pathway	
in	 glucocorticoid‐dependent	 severe	 asthma,	 moderate‐to‐severe	
uncontrolled	 asthma,176,177	 CRSwNP,178	 and	 atopic	 dermatitis179 
(dupilumab),	 by	 blocking	 IL‐5	 in	 severe	 eosinophilic	 asthma	 (me‐
polizumab,180	reslizumab181)	and	CRSwNP	and	severe	uncontrolled	
asthma	by	blocking	 the	 IL‐5	 receptor	 (benralizumab182,183).184	FDA	
and	EMA	approved	mepolizumab,	reslizumab,	and	benralizumab	for	










Phase	 II	 trials	 of	 biologics	 targeting	 type‐2	 pathways	 beyond	
IL‐4,	IL‐5,	and	IL‐13	are	encouraging.	Tezepelumab	blocking	the	TSLP	
receptor	 showed	 efficacy	 in	 uncontrolled	 asthma	 independent	 of	
eosinophil	counts.190	Nemolizumab	blocks	the	IL‐31R‐alpha	and	re‐
duces	pruritus	and	to	a	certain	extent	also	dermatitis	severity.191	It	
Unknowns in the treatment of food allergy
•	 Which	markers	predict	treatment	response?






•	 How	 can	 we	 implement	 oral	 immunotherapy	 safely	 in	 a	
community	setting?
•	 How	 to	 modify	 allergen	 formulations	 for	 tolerance	
induction?



























4.3 | Small molecules for the treatment of 
allergic asthma
Several	targeted	therapeutic	options	for	asthma	and	related	con‐
ditions	 have	 been	 licensed	 in	 the	 past	 two	decades.	Apart	 from	
parenteral	monoclonal	antibodies	directed	against	key	inflamma‐
tory	 targets,	small	molecules	comprise	another	class	of	systemic	
medication	 interfering	 with	 inflammatory	 pathways	 underlying	
these	 disorders.197	 Leukotriene	 modifiers	 (LM),	 and	 specifically	








More	 recently,	 another	 class	 of	 lipid	 mediator	 antagonists	
entered	 clinical	 development:	 antagonists	 of	 the	 prostaglandin	
D2	 (PGD2)	 receptor	 DP2	 also	 known	 as	 chemoattractant	 recep‐
tor‐homologous	 molecule	 expressed	 on	 Th2	 cells	 (CRTH2).200 
DP2/CRTH2	receptors	are	present	on	several	 inflammatory	cells	
including	mast	cells,	T‐helper	2	cells,	type	2	ILCs,	and	eosinophils,	
and	hence,	PGD2	plays	 an	 important	 role	 in	 linking	both	 the	 in‐
nate	 and	 adaptive	 immune	 system	 through	 type	2	 responses.201 
Although	 two	 compounds	 showed	 (modest)	 efficacy	 in	 allergen	
challenge,202,203	 many	 CRTH2	 antagonists	 failed	 in	 later	 clinical	





and/or	 refractory	 eosinophilic	 asthma,	 showing	 improvements	
in	several	clinical	outcomes.205‐209	In	a	post	hoc	analysis,	CRTH2	
antagonist	OC000459	 (Timapiprant)	 appeared	most	 effective	 in	
younger	(≤40	years)	patients	with	uncontrolled	atopic	eosinophilic	
asthma	 (blood	 eosinophils	 ≥	 250	 cells/μL).209	 Currently,	 several	
CRTH2	antagonist	programs	are	in	phase	III	studies	which	should	
help	 to	 consolidate	 phenotypes	 and	 biomarkers	 responding	 to	
these	 targeted	 drugs.	 Additionally,	 while	 the	 same	 immune/in‐
flammatory	cells	express	both	CysLT1	and	DP2/CRTH2	receptors,	
further	 research	 is	warranted	on	potential	 synergistic	 effects	of	
LTRA	and	CRTH2	antagonists	in	T2	inflammatory	conditions.
4.4 | Novel therapeutic concepts in AIT for 
airway disease
Allergen‐specific	 immunotherapy	 not	 only	 reduces	 symptoms	 in	
patients	with	AR,106	LAR,1	and	asthma,106,210	but	there	 is	also	evi‐
dence	 that	 AIT	 can	 reduce	 the	 development	 of	 asthma	 and	 new	
sensitizations,210‐212	thus	being	the	only	available	disease‐modifying	
treatment.	Altogether,	albeit	not	all	of	 the	highest	quality,	 there	 is	
evidence	that	AIT	can	halt	the	allergic	march	in	patients	with	AR.213 









limited	 penetration	 are	multifold16,103,222	 but	 the	 long	 duration	 of	
the	 treatment,	 the	 potential	 side	 effects	 especially	 in	 groups	 that	




patients	 in	 their	decisions.	However,	 for	 further	expansion	of	AIT,	
we	must	influence	the	balance	between	allergenicity	and	immuno‐
genicity,	which	can	improve	both	duration	of	treatment	and	create	
a	 better	 side	 effect	 profile.	 Furthermore,	we	 need	 greater	 under‐
standing	of	the	molecular	mechanisms	underlying	the	development	
Research needs for treatment with novel small 
molecules
•	 Sensitive	and	reliable	point‐of‐care	biomarkers	 to	 identify	
potential	 responders	 and	 to	 monitor	 (long‐term)	 effects	















Our	 specialty	has	been	evolving	at	 full	 speed	with	 the	 introduc‐
tion	 of	 several	 novel	 concepts	 such	 as	 knowledge	 of	 structures	
and	 biological	 functions	 of	 allergens	 to	 better	 understand	what	
makes	 them	allergenic,	molecular	mechanisms	of	 the	 type	2	 im‐
mune	response	and	 immune	tolerance.	Due	to	the	omics	revolu‐




the	 early	 days	 of	 the	 development	 of	 new	 biologicals	 that	 have	
entered	 the	 clinic.	 Small	 molecules	 and	 combinations	may	 offer	
a	 rational	 alternative	 for	 the	 treatment	 of	 specific	 subtypes	 of	
asthma	 and	 related	 diseases.	 Future	 studies	 and	 head‐to‐head	
comparisons	 with	 the	 more	 expensive	 biologics	 should	 provide	





cure	 in	many	 patients,	 and	 develop	 novel	 prevention	modalities	
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